EUVIMEDEUVIMED entdecken
Open Access

Gender Disparities in Breast Cancer Survival According to Clinical Treatment Score Post-5 Years (CTS5) Risk Stratification

Ke Liu, Zhen-Zhen Lu, Zhen-Yu He, San-Gang Wu

Cancer Research and Treatment · 2025

DOI: 10.4143/crt.2025.361 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Research and Treatment, 2025. Verfasst von Ke Liu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Xiamen Key Laboratory of Clinical Efficacy and Evidence Studies of Traditional Chinese Medicine, The First Affiliated Hospital of Xiamen University, …. Hauptthemen laut MEDLINE: Breast Neoplasms, Breast Neoplasms, Male. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Fujian Province, Guangdong Basic and Applied Basic Research Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: The role of the Clinical Treatment Score post-5 years (CTS5) in male breast cancer (MBC) remains unclear. This study aimed to investigate the characteristics and prognosis of CTS5 between MBC and female breast cancer (FBC). MATERIALS AND METHODS: Patients diagnosed with human epidermal growth factor receptor 2-negative/estrogen receptor-positive breast cancer between 2010 and 2015 were identified from the Surveillance, Epidemiology, and End Results (SEER) database. The chi-square test, Kaplan-Meier analysis, and multivariate Cox proportional hazard model were used for statistical analysis. RESULTS: This study included 169,869 patients, comprising 168,422 (99.1%) FBC and 1,447 (0.9%) MBC patients. More MBC patients had intermediate risk (IR)/high risk (HR) disease compared to FBC patients (17.7% vs. 8.7%, p < 0.001). MBC patients had an inferior overall survival (OS) but similar breast cancer-specific survival compared to those with FBC. Sensitivity analyses showed that sex was an independent prognostic factor associated with OS but not breast cancer-specific survival (BCSS) in both the low-risk (LR) and IR/HR cohorts. Those with MBC exhibited significantly worse OS (p < 0.001) than FBC patients in both cohorts. In MBC patients, those with IR/HR disease had significantly worse OS (p < 0.001) and BCSS (p < 0.001) compared to those with LR disease. For FBC patients, the IR/HR group had also significantly worse OS (p < 0.001) and BCSS (p < 0.001) compared to the LR group. CONCLUSION: Our findings highlight critical differences in clinical characteristics, treatment patterns, and outcomes between MBC and FBC, suggesting the need for sex-tailored approaches in breast cancer management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsBreast Neoplasms, MaleHumansFemaleMaleMiddle AgedPrognosisSEER ProgramAgedRisk AssessmentAdultSex FactorsKaplan-Meier Estimate

Stichwörter der Autor:innen

Breast neoplasmsCTS5FemaleMaleSurvival

Autor:innen und Institutionen

  • Xiamen Key Laboratory of Clinical Efficacy and Evidence Studies of Traditional Chinese Medicine, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.
  • The Graduate School of Fujian Medical University, Fuzhou, China.
  • Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China.
  • Department of Radiation Oncology, Xiamen Cancer Quality Control Center, Xiamen Cancer Center, Xiamen Key Laboratory of Radiation Oncology, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen U…

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Fujian Province
  • Guangdong Basic and Applied Basic Research Foundation
  • Social Development Projects of Key R&D Programs in Hainan Province
  • Project of the Xiamen Municipal Health Commission

Zitieren

APA

Liu, K., Lu, Z. Z., He, Z. Y., & Wu, S. G. (2025). Gender Disparities in Breast Cancer Survival According to Clinical Treatment Score Post-5 Years (CTS5) Risk Stratification. Cancer Research and Treatment. https://doi.org/10.4143/crt.2025.361

Vancouver

Liu K, Lu ZZ, He ZY, Wu SG. Gender Disparities in Breast Cancer Survival According to Clinical Treatment Score Post-5 Years (CTS5) Risk Stratification. Cancer Research and Treatment. 2025. doi:10.4143/crt.2025.361

BibTeX
@article{Liu2025,
  author = {Liu, Ke and Lu, Zhen-Zhen and He, Zhen-Yu and Wu, San-Gang},
  title = {Gender Disparities in Breast Cancer Survival According to Clinical Treatment Score Post-5 Years (CTS5) Risk Stratification},
  journal = {Cancer Research and Treatment},
  year = {2025},
  doi = {10.4143/crt.2025.361}
}
Kostenlos starten →